Dramatic improvement in severe-critical COVID-19 patient after tocilizumab administration: a clinical experience

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in coronavirus disease 2019 (COVID-19) involve so many inflammatory cytokines, especially Interleukin-6 (IL-6). The usage of tocilizumab as an anti-IL-6 receptor antibody had been approved as COVID-19 medication.Case Presentation: This article reports a 51-year-old woman diagnosed with severe-critical COVID-19. The patient made significant progress after tocilizumab administration. The patient was hospitalized for 14 days before being discharged.Conclusion: Tocilizumab administration showed a significant improvement in COVID-19 patients. However, further investigations are needed to explain this further.

The Journey of Clinical Manifestation Covid-19 After Favipiravir Treatment

“…In this study, the cough already decreased a half after day 7 and was only found at 16.7% on day 14, this is consistent with the manifestation was gotten better along with negative virus. [16].…”